Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth (Status and Outlook) 2025-2031
According to this study, the global Targeted Drug EGFR RTK Inhibitors for NSCLC market size will reach US$ million by 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug EGFR RTK Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug EGFR RTK Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug EGFR RTK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug EGFR RTK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug EGFR RTK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug EGFR RTK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug EGFR RTK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug EGFR RTK Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug EGFR RTK Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Forecast” looks at past sales and reviews total world Targeted Drug EGFR RTK Inhibitors for NSCLC sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drug EGFR RTK Inhibitors for NSCLC sales for 2025 through 2031. With Targeted Drug EGFR RTK Inhibitors for NSCLC sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drug EGFR RTK Inhibitors for NSCLC industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drug EGFR RTK Inhibitors for NSCLC landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drug EGFR RTK Inhibitors for NSCLC portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drug EGFR RTK Inhibitors for NSCLC market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drug EGFR RTK Inhibitors for NSCLC and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drug EGFR RTK Inhibitors for NSCLC.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Icotinib
- Gefitinib
- Erlotinib
- Afatinib
- Osimertinib
- Brigatinib
- Others
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Beta Pharma
- AstraZeneca
- Natco Pharma
- Qilu Pharmaceutical
- Genentech (Roche Group)
- Mylan
- Teva
- OSI Pharmaceuticals
- Glenmark Pharmaceuticals
- Beacon Pharmaceuticals
- Boehringer Ingelheim
- Pfizer
- ARIAD Pharmaceuticals (Takeda)
- Genvio Pharma Limited
- Drug International Limted
- Everest Pharmaceuticals
- Incepta Pharmaceuticals Limited
- Cipla Pharma
- Dr Reddy's Laboratories
- Zydus Cadila
- Hetero Drugs
- Intas Pharmaceuticals
- Alkem Laboratories
- RPG Life Sciences
- Fresenius Kabi India
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2020-2031)
2.1.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drug EGFR RTK Inhibitors for NSCLC by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Type
2.2.1 Icotinib
2.2.2 Gefitinib
2.2.3 Erlotinib
2.2.4 Afatinib
2.2.5 Osimertinib
2.2.6 Brigatinib
2.2.7 Others
2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
2.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
3 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Player
3.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Player (2020-2025)
3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC BY REGION
4.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025)
4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.4 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.5 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
5.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
5.3 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025)
6.2 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
6.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC by Region (2020-2025)
8.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2.2 Canada Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2.3 Mexico Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2.4 Brazil Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.3.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.2 Japan Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.3 Korea Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.4 Southeast Asia Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.5 India Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.6 Australia Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.2 France Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.3 UK Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.4 Italy Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.5 Russia Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5.2 South Africa Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5.3 Israel Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5.4 Turkey Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Type (2026-2031)
10.7 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
11 KEY PLAYERS ANALYSIS
11.1 Beta Pharma
11.1.1 Beta Pharma Company Information
11.1.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Beta Pharma Main Business Overview
11.1.5 Beta Pharma Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Qilu Pharmaceutical
11.4.1 Qilu Pharmaceutical Company Information
11.4.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Qilu Pharmaceutical Main Business Overview
11.4.5 Qilu Pharmaceutical Latest Developments
11.5 Genentech (Roche Group)
11.5.1 Genentech (Roche Group) Company Information
11.5.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Genentech (Roche Group) Main Business Overview
11.5.5 Genentech (Roche Group) Latest Developments
11.6 Mylan
11.6.1 Mylan Company Information
11.6.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Mylan Main Business Overview
11.6.5 Mylan Latest Developments
11.7 Teva
11.7.1 Teva Company Information
11.7.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Teva Main Business Overview
11.7.5 Teva Latest Developments
11.8 OSI Pharmaceuticals
11.8.1 OSI Pharmaceuticals Company Information
11.8.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 OSI Pharmaceuticals Main Business Overview
11.8.5 OSI Pharmaceuticals Latest Developments
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Information
11.9.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Glenmark Pharmaceuticals Main Business Overview
11.9.5 Glenmark Pharmaceuticals Latest Developments
11.10 Beacon Pharmaceuticals
11.10.1 Beacon Pharmaceuticals Company Information
11.10.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Beacon Pharmaceuticals Main Business Overview
11.10.5 Beacon Pharmaceuticals Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Pfizer
11.12.1 Pfizer Company Information
11.12.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Pfizer Main Business Overview
11.12.5 Pfizer Latest Developments
11.13 ARIAD Pharmaceuticals (Takeda)
11.13.1 ARIAD Pharmaceuticals (Takeda) Company Information
11.13.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 ARIAD Pharmaceuticals (Takeda) Main Business Overview
11.13.5 ARIAD Pharmaceuticals (Takeda) Latest Developments
11.14 Genvio Pharma Limited
11.14.1 Genvio Pharma Limited Company Information
11.14.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Genvio Pharma Limited Main Business Overview
11.14.5 Genvio Pharma Limited Latest Developments
11.15 Drug International Limted
11.15.1 Drug International Limted Company Information
11.15.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Drug International Limted Main Business Overview
11.15.5 Drug International Limted Latest Developments
11.16 Everest Pharmaceuticals
11.16.1 Everest Pharmaceuticals Company Information
11.16.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Everest Pharmaceuticals Main Business Overview
11.16.5 Everest Pharmaceuticals Latest Developments
11.17 Incepta Pharmaceuticals Limited
11.17.1 Incepta Pharmaceuticals Limited Company Information
11.17.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Incepta Pharmaceuticals Limited Main Business Overview
11.17.5 Incepta Pharmaceuticals Limited Latest Developments
11.18 Cipla Pharma
11.18.1 Cipla Pharma Company Information
11.18.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Cipla Pharma Main Business Overview
11.18.5 Cipla Pharma Latest Developments
11.19 Dr Reddy's Laboratories
11.19.1 Dr Reddy's Laboratories Company Information
11.19.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Dr Reddy's Laboratories Main Business Overview
11.19.5 Dr Reddy's Laboratories Latest Developments
11.20 Zydus Cadila
11.20.1 Zydus Cadila Company Information
11.20.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Zydus Cadila Main Business Overview
11.20.5 Zydus Cadila Latest Developments
11.21 Hetero Drugs
11.21.1 Hetero Drugs Company Information
11.21.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 Hetero Drugs Main Business Overview
11.21.5 Hetero Drugs Latest Developments
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Information
11.22.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.22.4 Intas Pharmaceuticals Main Business Overview
11.22.5 Intas Pharmaceuticals Latest Developments
11.23 Alkem Laboratories
11.23.1 Alkem Laboratories Company Information
11.23.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.23.4 Alkem Laboratories Main Business Overview
11.23.5 Alkem Laboratories Latest Developments
11.24 RPG Life Sciences
11.24.1 RPG Life Sciences Company Information
11.24.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.24.4 RPG Life Sciences Main Business Overview
11.24.5 RPG Life Sciences Latest Developments
11.25 Fresenius Kabi India
11.25.1 Fresenius Kabi India Company Information
11.25.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.25.4 Fresenius Kabi India Main Business Overview
11.25.5 Fresenius Kabi India Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2020-2031)
2.1.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Targeted Drug EGFR RTK Inhibitors for NSCLC by Country/Region (2020, 2024 & 2031)
2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Type
2.2.1 Icotinib
2.2.2 Gefitinib
2.2.3 Erlotinib
2.2.4 Afatinib
2.2.5 Osimertinib
2.2.6 Brigatinib
2.2.7 Others
2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
2.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Application
2.4.1 Squamous Cell Carcinoma of NSCLC
2.4.2 Adenocarcinoma of NSCLC
2.4.3 Large Cell Carcinoma of NSCLC
2.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application
2.5.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
3 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET SIZE BY PLAYER
3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Player
3.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Player (2020-2025)
3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC BY REGION
4.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025)
4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Annual Revenue by Country/Region (2020-2025)
4.3 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.4 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.5 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
4.6 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
5.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
5.3 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025)
6.2 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
6.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC by Region (2020-2025)
8.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025)
8.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUG EGFR RTK INHIBITORS FOR NSCLC MARKET FORECAST
10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.1.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.1.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2 Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.2.1 United States Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2.2 Canada Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2.3 Mexico Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.2.4 Brazil Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3 APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.3.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast
10.3.2 Japan Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.3 Korea Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.4 Southeast Asia Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.5 India Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.3.6 Australia Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Country (2026-2031)
10.4.1 Germany Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.2 France Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.3 UK Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.4 Italy Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.4.5 Russia Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Region (2026-2031)
10.5.1 Egypt Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5.2 South Africa Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5.3 Israel Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.5.4 Turkey Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
10.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Type (2026-2031)
10.7 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Targeted Drug EGFR RTK Inhibitors for NSCLC Forecast
11 KEY PLAYERS ANALYSIS
11.1 Beta Pharma
11.1.1 Beta Pharma Company Information
11.1.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Beta Pharma Main Business Overview
11.1.5 Beta Pharma Latest Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 AstraZeneca Main Business Overview
11.2.5 AstraZeneca Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Qilu Pharmaceutical
11.4.1 Qilu Pharmaceutical Company Information
11.4.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Qilu Pharmaceutical Main Business Overview
11.4.5 Qilu Pharmaceutical Latest Developments
11.5 Genentech (Roche Group)
11.5.1 Genentech (Roche Group) Company Information
11.5.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Genentech (Roche Group) Main Business Overview
11.5.5 Genentech (Roche Group) Latest Developments
11.6 Mylan
11.6.1 Mylan Company Information
11.6.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Mylan Main Business Overview
11.6.5 Mylan Latest Developments
11.7 Teva
11.7.1 Teva Company Information
11.7.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Teva Main Business Overview
11.7.5 Teva Latest Developments
11.8 OSI Pharmaceuticals
11.8.1 OSI Pharmaceuticals Company Information
11.8.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 OSI Pharmaceuticals Main Business Overview
11.8.5 OSI Pharmaceuticals Latest Developments
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Information
11.9.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Glenmark Pharmaceuticals Main Business Overview
11.9.5 Glenmark Pharmaceuticals Latest Developments
11.10 Beacon Pharmaceuticals
11.10.1 Beacon Pharmaceuticals Company Information
11.10.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Beacon Pharmaceuticals Main Business Overview
11.10.5 Beacon Pharmaceuticals Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Pfizer
11.12.1 Pfizer Company Information
11.12.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Pfizer Main Business Overview
11.12.5 Pfizer Latest Developments
11.13 ARIAD Pharmaceuticals (Takeda)
11.13.1 ARIAD Pharmaceuticals (Takeda) Company Information
11.13.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 ARIAD Pharmaceuticals (Takeda) Main Business Overview
11.13.5 ARIAD Pharmaceuticals (Takeda) Latest Developments
11.14 Genvio Pharma Limited
11.14.1 Genvio Pharma Limited Company Information
11.14.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Genvio Pharma Limited Main Business Overview
11.14.5 Genvio Pharma Limited Latest Developments
11.15 Drug International Limted
11.15.1 Drug International Limted Company Information
11.15.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Drug International Limted Main Business Overview
11.15.5 Drug International Limted Latest Developments
11.16 Everest Pharmaceuticals
11.16.1 Everest Pharmaceuticals Company Information
11.16.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Everest Pharmaceuticals Main Business Overview
11.16.5 Everest Pharmaceuticals Latest Developments
11.17 Incepta Pharmaceuticals Limited
11.17.1 Incepta Pharmaceuticals Limited Company Information
11.17.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Incepta Pharmaceuticals Limited Main Business Overview
11.17.5 Incepta Pharmaceuticals Limited Latest Developments
11.18 Cipla Pharma
11.18.1 Cipla Pharma Company Information
11.18.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Cipla Pharma Main Business Overview
11.18.5 Cipla Pharma Latest Developments
11.19 Dr Reddy's Laboratories
11.19.1 Dr Reddy's Laboratories Company Information
11.19.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Dr Reddy's Laboratories Main Business Overview
11.19.5 Dr Reddy's Laboratories Latest Developments
11.20 Zydus Cadila
11.20.1 Zydus Cadila Company Information
11.20.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Zydus Cadila Main Business Overview
11.20.5 Zydus Cadila Latest Developments
11.21 Hetero Drugs
11.21.1 Hetero Drugs Company Information
11.21.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.21.4 Hetero Drugs Main Business Overview
11.21.5 Hetero Drugs Latest Developments
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Information
11.22.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.22.4 Intas Pharmaceuticals Main Business Overview
11.22.5 Intas Pharmaceuticals Latest Developments
11.23 Alkem Laboratories
11.23.1 Alkem Laboratories Company Information
11.23.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.23.4 Alkem Laboratories Main Business Overview
11.23.5 Alkem Laboratories Latest Developments
11.24 RPG Life Sciences
11.24.1 RPG Life Sciences Company Information
11.24.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.24.4 RPG Life Sciences Main Business Overview
11.24.5 RPG Life Sciences Latest Developments
11.25 Fresenius Kabi India
11.25.1 Fresenius Kabi India Company Information
11.25.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2020-2025)
11.25.4 Fresenius Kabi India Main Business Overview
11.25.5 Fresenius Kabi India Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drug EGFR RTK Inhibitors for NSCLC Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Icotinib
Table 4. Major Players of Gefitinib
Table 5. Major Players of Erlotinib
Table 6. Major Players of Afatinib
Table 7. Major Players of Osimertinib
Table 8. Major Players of Brigatinib
Table 9. Major Players of Others
Table 10. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 12. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 13. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Player (2020-2025) & ($ millions)
Table 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
Table 18. Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
Table 19. Targeted Drug EGFR RTK Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 20. New Products and Potential Entrants
Table 21. Mergers & Acquisitions, Expansion
Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 23. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 24. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country/Region (2020-2025) & ($ millions)
Table 25. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country/Region (2020-2025)
Table 26. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 27. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 28. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 29. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 30. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 31. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 32. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 33. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 34. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 35. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 36. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 40. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 41. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 42. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 43. Key Market Drivers & Growth Opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 44. Key Market Challenges & Risks of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 45. Key Industry Trends of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 46. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Region (2026-2031) & ($ millions)
Table 47. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Region (2026-2031)
Table 48. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type (2026-2031) & ($ millions)
Table 49. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Application (2026-2031) & ($ millions)
Table 50. Beta Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 51. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 52. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Beta Pharma Main Business
Table 54. Beta Pharma Latest Developments
Table 55. AstraZeneca Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 56. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 57. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. AstraZeneca Main Business
Table 59. AstraZeneca Latest Developments
Table 60. Natco Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 61. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 62. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Natco Pharma Main Business
Table 64. Natco Pharma Latest Developments
Table 65. Qilu Pharmaceutical Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 66. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 67. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Qilu Pharmaceutical Main Business
Table 69. Qilu Pharmaceutical Latest Developments
Table 70. Genentech (Roche Group) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 71. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 72. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Genentech (Roche Group) Main Business
Table 74. Genentech (Roche Group) Latest Developments
Table 75. Mylan Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 76. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 77. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Mylan Main Business
Table 79. Mylan Latest Developments
Table 80. Teva Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 81. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 82. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Teva Main Business
Table 84. Teva Latest Developments
Table 85. OSI Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 86. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 87. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. OSI Pharmaceuticals Main Business
Table 89. OSI Pharmaceuticals Latest Developments
Table 90. Glenmark Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 91. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 92. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. Glenmark Pharmaceuticals Main Business
Table 94. Glenmark Pharmaceuticals Latest Developments
Table 95. Beacon Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 96. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 97. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 98. Beacon Pharmaceuticals Main Business
Table 99. Beacon Pharmaceuticals Latest Developments
Table 100. Boehringer Ingelheim Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 101. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 102. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 103. Boehringer Ingelheim Main Business
Table 104. Boehringer Ingelheim Latest Developments
Table 105. Pfizer Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 106. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 107. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 108. Pfizer Main Business
Table 109. Pfizer Latest Developments
Table 110. ARIAD Pharmaceuticals (Takeda) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 111. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 112. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 113. ARIAD Pharmaceuticals (Takeda) Main Business
Table 114. ARIAD Pharmaceuticals (Takeda) Latest Developments
Table 115. Genvio Pharma Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 116. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 117. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 118. Genvio Pharma Limited Main Business
Table 119. Genvio Pharma Limited Latest Developments
Table 120. Drug International Limted Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 121. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 122. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 123. Drug International Limted Main Business
Table 124. Drug International Limted Latest Developments
Table 125. Everest Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 126. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 127. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 128. Everest Pharmaceuticals Main Business
Table 129. Everest Pharmaceuticals Latest Developments
Table 130. Incepta Pharmaceuticals Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 131. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 132. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 133. Incepta Pharmaceuticals Limited Main Business
Table 134. Incepta Pharmaceuticals Limited Latest Developments
Table 135. Cipla Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 136. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 137. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 138. Cipla Pharma Main Business
Table 139. Cipla Pharma Latest Developments
Table 140. Dr Reddy's Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 141. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 142. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 143. Dr Reddy's Laboratories Main Business
Table 144. Dr Reddy's Laboratories Latest Developments
Table 145. Zydus Cadila Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 146. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 147. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 148. Zydus Cadila Main Business
Table 149. Zydus Cadila Latest Developments
Table 150. Hetero Drugs Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 151. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 152. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 153. Hetero Drugs Main Business
Table 154. Hetero Drugs Latest Developments
Table 155. Intas Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 156. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 157. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 158. Intas Pharmaceuticals Main Business
Table 159. Intas Pharmaceuticals Latest Developments
Table 160. Alkem Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 161. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 162. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 163. Alkem Laboratories Main Business
Table 164. Alkem Laboratories Latest Developments
Table 165. RPG Life Sciences Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 166. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 167. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 168. RPG Life Sciences Main Business
Table 169. RPG Life Sciences Latest Developments
Table 170. Fresenius Kabi India Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 171. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 172. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 173. Fresenius Kabi India Main Business
Table 174. Fresenius Kabi India Latest Developments
Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Targeted Drug EGFR RTK Inhibitors for NSCLC Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Icotinib
Table 4. Major Players of Gefitinib
Table 5. Major Players of Erlotinib
Table 6. Major Players of Afatinib
Table 7. Major Players of Osimertinib
Table 8. Major Players of Brigatinib
Table 9. Major Players of Others
Table 10. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 12. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 13. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Player (2020-2025) & ($ millions)
Table 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player (2020-2025)
Table 18. Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Products Offered
Table 19. Targeted Drug EGFR RTK Inhibitors for NSCLC Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 20. New Products and Potential Entrants
Table 21. Mergers & Acquisitions, Expansion
Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 23. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 24. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Country/Region (2020-2025) & ($ millions)
Table 25. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Country/Region (2020-2025)
Table 26. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 27. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 28. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 29. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Table 30. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 31. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Table 32. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 33. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Table 34. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 35. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 36. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & ($ millions)
Table 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country (2020-2025)
Table 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 40. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & ($ millions)
Table 41. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & ($ millions)
Table 42. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & ($ millions)
Table 43. Key Market Drivers & Growth Opportunities of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 44. Key Market Challenges & Risks of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 45. Key Industry Trends of Targeted Drug EGFR RTK Inhibitors for NSCLC
Table 46. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Region (2026-2031) & ($ millions)
Table 47. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Region (2026-2031)
Table 48. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type (2026-2031) & ($ millions)
Table 49. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Application (2026-2031) & ($ millions)
Table 50. Beta Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 51. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 52. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Beta Pharma Main Business
Table 54. Beta Pharma Latest Developments
Table 55. AstraZeneca Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 56. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 57. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. AstraZeneca Main Business
Table 59. AstraZeneca Latest Developments
Table 60. Natco Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 61. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 62. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Natco Pharma Main Business
Table 64. Natco Pharma Latest Developments
Table 65. Qilu Pharmaceutical Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 66. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 67. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Qilu Pharmaceutical Main Business
Table 69. Qilu Pharmaceutical Latest Developments
Table 70. Genentech (Roche Group) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 71. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 72. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Genentech (Roche Group) Main Business
Table 74. Genentech (Roche Group) Latest Developments
Table 75. Mylan Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 76. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 77. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Mylan Main Business
Table 79. Mylan Latest Developments
Table 80. Teva Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 81. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 82. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Teva Main Business
Table 84. Teva Latest Developments
Table 85. OSI Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 86. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 87. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. OSI Pharmaceuticals Main Business
Table 89. OSI Pharmaceuticals Latest Developments
Table 90. Glenmark Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 91. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 92. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. Glenmark Pharmaceuticals Main Business
Table 94. Glenmark Pharmaceuticals Latest Developments
Table 95. Beacon Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 96. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 97. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 98. Beacon Pharmaceuticals Main Business
Table 99. Beacon Pharmaceuticals Latest Developments
Table 100. Boehringer Ingelheim Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 101. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 102. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 103. Boehringer Ingelheim Main Business
Table 104. Boehringer Ingelheim Latest Developments
Table 105. Pfizer Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 106. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 107. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 108. Pfizer Main Business
Table 109. Pfizer Latest Developments
Table 110. ARIAD Pharmaceuticals (Takeda) Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 111. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 112. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 113. ARIAD Pharmaceuticals (Takeda) Main Business
Table 114. ARIAD Pharmaceuticals (Takeda) Latest Developments
Table 115. Genvio Pharma Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 116. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 117. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 118. Genvio Pharma Limited Main Business
Table 119. Genvio Pharma Limited Latest Developments
Table 120. Drug International Limted Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 121. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 122. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 123. Drug International Limted Main Business
Table 124. Drug International Limted Latest Developments
Table 125. Everest Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 126. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 127. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 128. Everest Pharmaceuticals Main Business
Table 129. Everest Pharmaceuticals Latest Developments
Table 130. Incepta Pharmaceuticals Limited Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 131. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 132. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 133. Incepta Pharmaceuticals Limited Main Business
Table 134. Incepta Pharmaceuticals Limited Latest Developments
Table 135. Cipla Pharma Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 136. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 137. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 138. Cipla Pharma Main Business
Table 139. Cipla Pharma Latest Developments
Table 140. Dr Reddy's Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 141. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 142. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 143. Dr Reddy's Laboratories Main Business
Table 144. Dr Reddy's Laboratories Latest Developments
Table 145. Zydus Cadila Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 146. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 147. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 148. Zydus Cadila Main Business
Table 149. Zydus Cadila Latest Developments
Table 150. Hetero Drugs Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 151. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 152. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 153. Hetero Drugs Main Business
Table 154. Hetero Drugs Latest Developments
Table 155. Intas Pharmaceuticals Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 156. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 157. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 158. Intas Pharmaceuticals Main Business
Table 159. Intas Pharmaceuticals Latest Developments
Table 160. Alkem Laboratories Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 161. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 162. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 163. Alkem Laboratories Main Business
Table 164. Alkem Laboratories Latest Developments
Table 165. RPG Life Sciences Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 166. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 167. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 168. RPG Life Sciences Main Business
Table 169. RPG Life Sciences Latest Developments
Table 170. Fresenius Kabi India Details, Company Type, Targeted Drug EGFR RTK Inhibitors for NSCLC Area Served and Its Competitors
Table 171. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Offered
Table 172. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 173. Fresenius Kabi India Main Business
Table 174. Fresenius Kabi India Latest Developments
LIST OF FIGURES
Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type in 2024
Figure 10. Targeted Drug EGFR RTK Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 12. Targeted Drug EGFR RTK Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2020-2025) & ($ millions)
Figure 14. Targeted Drug EGFR RTK Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application in 2024
Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player in 2024
Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 19. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 20. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 21. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 23. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Value Market Share by Country in 2024
Figure 24. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region in 2024
Figure 29. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 30. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 31. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 35. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country in 2024
Figure 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 40. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 41. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 54. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 55. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 57. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 58. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 59. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 60. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 61. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 62. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 63. Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 65. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 66. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 67. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 68. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 69. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 70. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 71. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 72. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 73. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 74. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 75. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 76. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2024)
Figure 8. Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type in 2024
Figure 10. Targeted Drug EGFR RTK Inhibitors for NSCLC in Squamous Cell Carcinoma of NSCLC
Figure 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Squamous Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 12. Targeted Drug EGFR RTK Inhibitors for NSCLC in Adenocarcinoma of NSCLC
Figure 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Adenocarcinoma of NSCLC (2020-2025) & ($ millions)
Figure 14. Targeted Drug EGFR RTK Inhibitors for NSCLC in Large Cell Carcinoma of NSCLC
Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Large Cell Carcinoma of NSCLC (2020-2025) & ($ millions)
Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application in 2024
Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Player in 2024
Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 19. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 20. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 21. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2020-2025 ($ millions)
Figure 23. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Value Market Share by Country in 2024
Figure 24. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region in 2024
Figure 29. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 30. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 31. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 35. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Country in 2024
Figure 38. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 40. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 41. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 54. APAC Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 55. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 57. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 58. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 59. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 60. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 61. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 62. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 63. Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 65. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 66. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 67. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 68. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 69. UK Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 70. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 71. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 72. Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 73. South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 74. Israel Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 75. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
Figure 76. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2026-2031 ($ millions)
More Publications
Global Cox-2 Inhibitors Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
89 pages
Global PD-1 Inhibitor Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
92 pages
Global Drug Delivery in Cancer Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
141 pages
Global Selective Cox-2 Inhibitors Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
167 pages
